ArticleRisk analysis : an official publication of the Society for Risk Analysis2012
Chapter 7: Description of MISCAN-lung, the Erasmus MC Lung Cancer microsimulation model for evaluating cancer control interventions.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Trial
- Cost-Effectiveness of Universal Low-Dose Computed Tomographic Lung Cancer Screening in Singapore.JAMA network open · 2026Article
- Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- A Scoping Review on Calibration Methods for Cancer Simulation Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025Article
- The NCC mathematical modeling framework for decision-making of six major cancers.Journal of the National Cancer Center · 2023Article
- A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.Journal of the National Cancer Institute · 2020Article
- Predicting the Epidemiological Dynamics of Lung Cancer in Japan.Journal of clinical medicine · 2019Article
- The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.Cancer informatics · 2016Article
- Chapter 13: CISNET lung models: comparison of model assumptions and model structures.Risk analysis : an official publication of the Society for Risk Analysis · 2012Article
- Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models.Risk analysis : an official publication of the Society for Risk Analysis · 2012Article
- Chapter 8: The FHCRC lung cancer model.Risk analysis : an official publication of the Society for Risk Analysis · 2012Article
- Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control.Risk analysis : an official publication of the Society for Risk Analysis · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The MISCAN-lung model was designed to simulate population trends in lung cancer (LC) for comprehensive surveillance of the disease, to relate past exposure to risk factors to (observed) LC incidence and mortality, and to estimate the impact of cancer-control interventions. MISCAN-lung employs the technique of stochastic microsimulation of life histories affected by risk factors. It includes the two-stage clonal expansion model for carcinogenesis and a detailed LC progression model; the latter is specifically intended for the evaluation of screenings. This article elucidates further the principles of MISCAN-lung and describes its application to a comparative study within the CISNET Lung Working Group on the impact of tobacco control on U.S. LC mortality. MISCAN-lung yields an estimate of the number of LC deaths avoided during 1975-2000. The potential number of avoidable LC deaths, had everybody quit smoking in 1965, is 2.2 million; 750,000 deaths (30%) were avoided in the United States due to actual tobacco control interventions. The model fits in the actual tobacco-control scenario, providing credibility to the estimates of other scenarios, although considering survey-reported smoking trends alone has limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.